CHRISTOPHER U. MISSLING - 28 Apr 2025 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVXL	Stock Option (Right to Buy)	Award	$0	+125,000		$0.000000	125,000	28 Apr 2025	Common Stock	125,000	$8.57	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.